|
|
News Breaks | | | | September 7, 2012 | | 08:32 EDT |  | HPTX | Hyperion Therapeutics is significantly undervalued, says Cowen
Cowen said Hyperion Therapeutics is significantly undervalued following Q2 results. The firm cited its pipeline and cash funding and remains optimistic that Ravicti will be approved during the first half of 2013. Shares are Outperform rated. | |
|
News For HPTX From The Last 14 Days Check below for free stories on HPTX the last two weeks. |
|
|
| May 9, 2013 | | 16:27 EDT |  | HPTX | Hyperion Therapeutics reports Q1 EPS (52c), consensus (58c)
 Subscribe for More Information | |
|
|
|
|
|
|
